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 Th e use of statins in the general popula-
tion to reduce cardiovascular risk and 
patient mortality has been very well doc-
umented ( Figure 1 ). However, most of 
these studies have systematically excluded 
patients with renal failure. In patients 
with chronic kidney disease (CKD) and, 
especially, end-stage renal disease, the 
morta lity rate from cardiac disease and 
the burden of peripheral vascular disease 
are substantial compared with those in 
the nonrenal population.  Post hoc analy-
ses from statin studies in the general 
population, including primary- and 
 secondary-prevention studies, have dem-
onstrated that patients with moderately 
reduced renal function may benefi t from 
the use of statins, leading to a reduction 
in cardiac or cardiovascular events. 1,2 
Still, these  post hoc reports with fairly 
small subgroups of patients are not pow-
ered to make these claims. In addition, 
studies such as the renal Treating to New 
Targets (TNT) trial  compared diff erent 
doses of statins, showing a greater risk 
reduction with a higher dose and an eff ect 
size that seemed larger than that seen in 
the group with glomerular fi ltration rate 
(GFR) greater than 65  ml / min. 3 
 Similarly, there is a paucity of studies in 
the renal transplant population. Seven 
years ago, the first such study in renal 
transplant patients was published, 4 show-
ing that the combined end point of cardiac 
death or nonfatal myocardial infarction 
(MI) was signifi cantly reduced. Further-
more, the primary end point of major 
adverse cardiac events was also signi-
fi cantly reduced in the extended study 
with 2 more years of follow-up. 5 However, 
the primary end point of major adverse 
cardiac events was negative in both the 
Deutsche Diabetes Dialysis (4D) Study in 
diabetic patients on hemodialysis treat-
ment 6 and the AURORA trial, 7 two large-
scale randomized controlled trials in 
hemodialysis patients. In a  post hoc analy-
sis of the AURORA trial, diabetic patients 
appeared to do better on a statin with 
respect to cardiovascular end points. 
 Szummer  et al. 8 (this issue) performed 
an observational study of data in the 
SWEDEHEART registry, including more 
than 42,000 patients admitted to Swedish 
cardiology intensive care units for MI 
from 2003 to 2006. Th e authors investi-
gated statin use and its eff ects in relation 
to renal function following discharge of 
survivors. Th e use of statins at discharge 
was signifi cantly lower in patients with 
renal failure than in those with normal 
renal function: 81 % in CKD class 1 
(GFR   >  90  ml / min), 29 % in CKD 4 (GFR 
15 – 30  ml / min), and 31 % in CKD 5 
(GFR   <  15  ml / min or patient on dialysis). 
Th e 1-year follow-up on mortality dem-
onstrated a signifi cant interaction between 
a reduction in mortality at 1 year (registry 
data) and a decreasing GFR ( P  <  0.0001), 
interesting results since they demonstrate 
a larger eff ect size with better renal func-
tion. Th e overall reduction of mortality 
risk by statins was 37 % . Even in CKD 4, 
there was a signifi cant 1-year mortality 
risk reduction of 27 % , whereas in CKD 5, 
there was no effect at all, but a trend 
toward increased risk. 
 Of course, this observational study has 
limitations, as treatment was not rand-
omized, and the study lacks a control arm. 
Th e authors attempted to adjust for poten-
tially important confounding factors by 
defi ning a propensity score with a large 
number of factors for statin and non-
 statin treatment. Still, there were clear 
fi ndings about eff ect dependence on renal 
function. A sensitivity analysis for missing 
data did not change the overall results. 
Furthermore, the outcome is limited to 
mortality based on death registries; no 
other cardiovascular end point, such as 
cardiac or cardiovascular morbidity or 
mortality, was captured in this study. In 
addition, there was no indepen dent critical 
events committee to adjudicate the end 
points occurring in the study. 
 Th e advantage of such an observational 
study is that the cohort may be more rep-
resentative of the real population than 
when patients are entered into a control-
led, randomized study with exclusion and 
inclusion criteria. The findings of 
Szummer  et al. 8 are interesting in that 
sense, notwithstanding the limitations of 
a non-randomized trial. 
 In a previous communication regarding 
the same registry, the authors also identi-
fi ed the likelihood that active interven-
tional treatment of MI using percutaneous 
transluminal coronary angioplasty, stent-
ing, or coronary artery bypass graft  ing 
was related to renal dysfunction at admit-
tance, showing that the eligibility for 
active intervention decreased substantially 
with the degree of renal failure. 9 Interven-
tion was given to only 15 % of patients 
with advanced renal failure (CKD 5), as 
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 The observational study by Szummer  et al. shows that patients with advanced 
chronic kidney disease (CKD) are treated less with statins after myocardial 
infarction, even though statins benefit survival in CKD classes 1 – 4. The study ’ s 
limitations are obvious, but such a population may be more representative. 
The results indicate that statins should be used more frequently after 
myocardial infarction in CKD classes lower than 5, a conclusion supported by 
the recently presented Study of Heart and Renal Protection (SHARP). 
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compared with 62 % of those with normal 
renal function. However, the benefit 
declined with lower renal function. 
 The largest-ever statin trial in renal 
patients is the Study of Heart and Renal 
Protection (SHARP), 10 in which 9438 
CKD patients were randomized — 6382 
predialysis patients and 3056 dialysis 
patients, of whom 2540 were on hemo-
dialysis and 496 on peritoneal dialysis. Th ey 
were treated with either 20  mg simvastatin 
plus 10  mg ezetimibe or placebo over 4.9 
years of follow-up and showed a 16.5 % 
overall risk reduction ( P  <  0.0022) in the 
primary atherosclerotic end point (the pri-
mary end point was changed in 2009 
before unblinding). In addition, the origi-
nal end point of major adverse cardiac 
events was positive, with a 16.1 % risk 
reduction ( P  <  0.0010). It seems as if there 
may be a higher eff ect size in predialysis 
than in dialysis patients with CKD, about 
20 % versus about 10 % , according to the 
presentation at the ASN, and data on the 
website of SHARP. But apparently no sig-
nifi cant interaction was observed between 
the two subgroups ( P  =  0.25), indicating 
that they should be treated as one cohort. 
In the dialysis cohort alone, the effect 
seems to be a non-signifi cant risk reduc-
tion of about 10 % in dialysis patients, 
which is in accordance with the two previ-
ous statin trials in dialysis patients (8 % in 
the 4D Study and 4 % in AURORA, not 
signifi cant); the low-density lipoprotein 
reduction was of similar magnitude in 
the three studies, or even a bit higher 
in AURORA (1.1  mmol / l) and 4D 
(1.3  mmol / l) than in SHARP (0.85  mmol / l). 
Unfortunately, no publication is available 
at the moment from SHARP, and thus the 
medical community has to confine its 
opinion to what has been presented at the 
American Society of Nephrology and 
uploaded to the SHARP website ( www.
sharpinfo.org ). No substudy has been pre-
sented yet to show whether division into 
subgroups by low-density lipoprotein level 
infl uences the outcome. A publication is 
under way, however. 
 In summary, the observational study by 
Szummer  et al. 8 based on the SWEDE-
HEART registry demonstrates that renal 
patients are less likely to receive statin 
treatment upon discharge from the hospi-
tal after an acute MI and that this is 
strongly related to the degree of renal dys-
function, despite the fact that an eff ect on 
survival at 1 year seems to be present in 
CKD 1 – 4 (GFR   >  15  ml / min), as well as a 
less obvious eff ect in CKD 5. Th e limita-
tions of such an observational, unrand-
omized design need to be recognized, but 
it should also be appreciated that in such 
studies the patients may be more repre-
sentative of a real patient population. Th e 
results indicate that statins should be used 
more frequently than they are aft er MI, at 
least in CKD classes lower than 5. Th is 
view gains support from the recent SHARP 
trial, the largest-ever randomized primary-
prevention statin trial in renal patients. 
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 Figure 1  |  Factors influencing the accelerated cardiovascular disease (CVD) in chronic kidney 
disease (CKD). Factors potentially targeted by statins are highlighted in blue (dyslipidemia, 
inflammation, and endothelial dysfunction). AGEs, advanced gylcosylation end products; 
AOPP, advanced oxidation protein products; Ca, calcium; HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); P, phosphorus; 
PTH, parathyroid hormone; ROS, reactive oxidative species. 
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